New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial

By Pooja Toshniwal PahariaMay 28 2024Reviewed by Susha Cheriyedath, M.Sc. In a recent study published in the journal Nature Medicine , researchers conducted a randomized, double-blinded, placebo-controlled phase 2a trial to investigate the safety and efficacy of LM11A-31 in managing Alzheimer's disease through p75 neurotrophin receptor modulation.

About the study In the present randomized clinical trial, researchers investigated whether LM11A-31 could delay the progression of Alzheimer's disease by modulating p75NTR in humans. The primary outcome was safety and tolerability, assessed using the Columbia Suicide Severity Rating Scale , vital signs, blood pressure, and hematological parameters. The study used structural magnetic resonance imaging , fluorodeoxyglucose-positron emission tomography , and CSF biomarkers to assess secondary cognitive outcomes in Alzheimer's disease. AD indicators include tau phosphorylated at Thr181, total tau protein, Aβ40, Aβ42, and AChE activity.

Results The study found that LM11A-31 is safe and acceptable, with no serious safety concerns. Pervasive side effects include headache, diarrhea, eosinophilia, and nasopharyngitis, with gastrointestinal problems and eosinophilia being the most prevalent reasons for stopping. The 400-mg group saw greater medication discontinuations than the 200-mg and placebo groups. MRI found no concerns regarding medication safety, including amyloid-related imaging abnormalities.

Source: Healthcare Press (healthcarepress.net)

Alzheimer's Disease Biomarker Brain Cortex Dementia Drugs Efficacy Eosinophilia Glucose Imaging Medicine Pathophysiology Placebo Preclinical Protein Receptor Synapse Tau Protein

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Banking behavior could be used to detect early Alzheimer's, finds new researchAlzheimer's Disease can be detected years in advance of a clinical diagnosis by monitoring how people manage their finances, according to new research.
Source: medical_xpress - 🏆 101. / 51 Read more »

Scientists say they have identified a new genetic form of Alzheimer’s diseaseFindings suggest people who have two copies of the APOE4 gene are likely to develop the neurological condition.
Source: Glasgow_Times - 🏆 76. / 59 Read more »

Scientists say they have identified a new genetic form of Alzheimer’s diseaseFindings suggest people who have two copies of the APOE4 gene are likely to develop the neurological condition.
Source: Observer_Owl - 🏆 18. / 72 Read more »

Scientists identify new form of Alzheimer’s disease that 95% of gene carriers developAlmost everyone over the age of 65 who carries two copies of the APOE4 gene variant showed early signs of the disease making it a distinct genetic form of Alzheimer's, scientists said.
Source: i newspaper - 🏆 8. / 89 Read more »

New form of Alzheimer’s identified that 95% of gene carriers developAlmost everyone over the age of 65 who carries two copies of the APOE4 gene variant showed early signs of the disease making it a distinct genetic form of Alzheimer's, scientists said.
Source: i newspaper - 🏆 8. / 89 Read more »

Discovery of new Alzheimer’s gene risk could lead to earlier interventionsThe promising discovery will raise hopes of improved earlier testing and prevention
Source: i newspaper - 🏆 8. / 89 Read more »